These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Nov 6, 2019
- New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated...
Nov 4, 2019
- MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019 - VANCOUVER, Nov. 4, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on...
Aug 8, 2019
- Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 - - Exploring non-dilutive options to support future continued development of DDR portfolio -...
Aug 7, 2019
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...
Jun 27, 2019Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets
- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Exploring non-dilutive options to support future continued development of SRA737 and SRA141 -...